Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2014/295323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560713823944704 |
|---|---|
| author | Han-Mou Tsai Elizabeth Kuo |
| author_facet | Han-Mou Tsai Elizabeth Kuo |
| author_sort | Han-Mou Tsai |
| collection | DOAJ |
| description | Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA. |
| format | Article |
| id | doaj-art-1025c7e456f143628564a22867e5f84a |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-1025c7e456f143628564a22867e5f84a2025-02-03T01:26:52ZengWileyAdvances in Hematology1687-91041687-91122014-01-01201410.1155/2014/295323295323Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic SyndromeHan-Mou Tsai0Elizabeth Kuo1iMAH Hematology Associates, New Hyde Park, NY 11040, USADepartment of Medicine, University of Texas Southwestern School of Medicine, Dallas, TX 75235, USAEculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy for aHUS. The results show that, in patients with aHUS, eculizumab therapy, when not accompanied with concurrent plasma exchange therapy, led to steady increase in the platelet count and improvement in extra-renal complications within 3 days. By day 7, the platelet count was normal in 15 of 17 cases. The resolution of hemolytic anemia and improvement in renal function were less predictable and were not apparent for weeks to months in two patients. The swift response in the platelet counts was only observed in one of five cases who received concurrent plasma exchange therapy and was not observed in a case of TMA due to gemcitabine/carboplatin. In summary, eculizumab leads to rapid increase in the platelet counts and resolution of extrarenal symptoms in patients with aHUS. Concurrent plasma exchange greatly impedes the response of aHUS to eculizumab therapy. Eculizumab is ineffective for gemcitabine/carboplatin associated TMA.http://dx.doi.org/10.1155/2014/295323 |
| spellingShingle | Han-Mou Tsai Elizabeth Kuo Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome Advances in Hematology |
| title | Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome |
| title_full | Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome |
| title_fullStr | Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome |
| title_full_unstemmed | Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome |
| title_short | Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome |
| title_sort | eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome |
| url | http://dx.doi.org/10.1155/2014/295323 |
| work_keys_str_mv | AT hanmoutsai eculizumabtherapyleadstorapidresolutionofthrombocytopeniainatypicalhemolyticuremicsyndrome AT elizabethkuo eculizumabtherapyleadstorapidresolutionofthrombocytopeniainatypicalhemolyticuremicsyndrome |